Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study
Journal of Clinical Medicine · 09.01.2024 · 13 (2) · 365
DOI: 10.3390/jcm13020365 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.01.2024. Verfasst von Tom Holvoet und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of the current study was to assess the safety and effectiveness of both in an elderly real-life population.
Methods
A multicentric retrospective study was performed on IBD patients who started vedolizumab or ustekinumab between 2010 and 2020. Clinical and endoscopic remission rates and (serious) adverse events (AE) were assessed.
Results
A total of 911 IBD patients were included, with 171 (19%) aged above 60 (111 VDZ, 60 UST). Elderly patients treated with vedolizumab or ustekinumab had an increased risk for non-IBD hospitalization (10.5% vs. 5.7%, p = 0.021) and malignancy (2.3% vs. 0.5%, p = 0.045) compared to the younger population. Corticosteroid-free clinical (50% vs. 44%; p = 0.201) and endoscopic remission rates (47.9% vs. 31%, p = 0.07) at 1 year were similar. Comparing vedolizumab to ustekinumab in the elderly population, corticosteroid-free (47.9% vs. 31%, p = 0.061) and endoscopic remission rates (66.7% vs. 64.4%, p = 0.981) were similar. Vedolizumab- and ustekinumab-treated patients had comparable infection rates (13.5% vs. 10.0%, p = 0.504), IBD flare-ups (4.5% vs. 5%, p = 1.000), the occurrence of new EIMs (13.5% vs. 10%, p = 0.504), a risk of intestinal surgery (5.4% vs. 6.7%, p = 0.742), malignancy (1.8% vs. 3.3%, p = 0.613), hospitalization (9.9% vs. 11.7%, p = 0.721), and mortality (0.9% vs. 1.7%, p = 1.000). AE risk was associated only with corticosteroid use.
Conclusions
Ustekinumab and vedolizumab show comparable effectiveness and safety in the elderly IBD population. Elderly IBD patients have an increased risk for non-IBD hospitalizations and malignancy compared to the younger IBD population, with corticosteroid use as the main risk factor.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.
- Ghent Gut Inflammation Group (GGIG), Ghent University, 9000 Ghent, Belgium.
- Department of Gastroenterology, VITAZ, 9100 Sint-Niklaas, Belgium.
- Department of Gastroenterology, UZ Ghent, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
- VIB Center for Inflammation Research (IRC), Ghent University, 9000 Ghent, Belgium.
- Department of Gastroenterology, University Hospital Ghent, 9000 Ghent, Belgium.
ORCID-Profile: Francisco Mesonero Gismero, Yamile Zabana, Jeroen Geldof, Triana Lobatón
Zitieren
APA
Holvoet, T., Truyens, M., De Galan, C., Peeters, H., Gismero, F. M., Elorza, A., Torres, P., Vandermeulen, L., Jauregui-Amezaga, A., Ferreiro-Iglesias, R., Zabana, Y., Reverter, L. P., Geldof, J., & Lobatón, T. (2024). Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. Journal of Clinical Medicine, 13(2), 365. https://doi.org/10.3390/jcm13020365
Vancouver
Holvoet T, Truyens M, De Galan C, Peeters H, Gismero FM, Elorza A, et al. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. Journal of Clinical Medicine. 2024;13(2):365. doi:10.3390/jcm13020365
BibTeX
@article{Holvoet2024,
author = {Holvoet, Tom and Truyens, Marie and De Galan, Cara and Peeters, Harald and Gismero, Francisco Mesonero and Elorza, Ainara and Torres, Paola and Vandermeulen, Liv and Jauregui-Amezaga, Aranzazu and Ferreiro-Iglesias, Rocio and Zabana, Yamile and Reverter, Laia Peries and Geldof, Jeroen and Lobatón, Triana},
title = {Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {2},
pages = {365},
doi = {10.3390/jcm13020365}
}
EUVIMED